Scientists know a lot about the virus that causes Ebola — but there are many puzzles that they have yet to solve.

NATURE SCIENCE International Weekly Journal of Science                                   Oct. 29, 2014

To much of the world, the virus behind the devastating Ebola outbreak in Africa seems to have stormed out of nowhere. But Leslie Lobel thinks we should have seen it coming.

In 2012, Lobel and a team of researchers spent six months in Uganda studying the Ebola virus and related viruses. Over the course of their stay, these pathogens caused at least four separate outbreaks of disease in central Africa, affecting more than 100 people. To Lobel, a virologist at Ben-Gurion University of the Negev in Beer-Sheva, Israel, the outbreaks felt like the small tremors that can precede a major earthquake. “We all said, something is going on here; something big is going to happen,” he says.

ASSOCIATED PRESS                                 Oct. 28, 2014
  GENEVA-- The Swiss agency that regulates new drugs said Tuesday it has approved an application for a clinical trial with an experimental Ebola vaccine at the Lausanne University Hospital.

In this picture provided by the World Health Organization, a package of vials of the first shipment of the experimental vaccine VSE-EBOV is opened at the Geneva Cantonal hospital on Wednesday, Oct. 22, 2014. The World Health Organization (WHO) welcomes the donation by the government of Canada of 800 vials of an experimental candidate vaccine, VSV-EBOV, against Ebola virus disease. Clinical safety trials with this experimental Ebola vaccine have already begun in healthy human volunteers in Mali, the United Kingdom and the United States after showing very promising results in animal research. . (AP Photo/WHO/Mathilde Missioneiro) 

Swissmedic said the trial will be conducted among 120 volunteer participants with support from the U.N. World Health Organization. The experimental vaccine is to be initially administered on healthy volunteers who will be sent as medical staff to fight the Ebola epidemic in West Africa.

SCIENCE INSIDER

By Jon Cohen and  Kai Kupferschmidt                          OCT.23, 2014

Extensive background documents from a meeting that took place today at the World Health Organization (WHO) have provided new details about exactly what it will take to test, produce, and bankroll Ebola vaccines, which could be a potential game changer in the epidemic.

ScienceInsider obtained materials that vaccinemakers, governments, and WHO provided to the 100 or so participants at a meeting on “access and financing” of Ebola vaccines. The documents put hard numbers on what until now have been somewhat fuzzy academic discussions. And they make clear to the attendees—who include representatives from governments, industry, philanthropies, and nongovernmental organizations—that although testing and production are moving forward at record speed, knotty issues remain. 

Read complete article

http://news.sciencemag.org/health/2014/10/leaked-documents-reveal-behind-scenes-ebola-vaccine-issues

HOMELAND SECURITY NEWS WIRE                                         Oct. 22, 2014

Two Ebola researchers suggest that as Ebola continues to spread in West Africa, it may be silently immunizing large numbers of people who never fall ill or infect others, yet become protected from future infection. If such immunity is confirmed, it would have significant ramifications on projections of how widespread the disease will be and could help determine strategies that health workers use to contain the disease, according to a letter published last week in The Lancet medical journal.   http://download.thelancet.com/flatcontentassets/pdfs/PIIS0140673614618390.pdf?id=aaadpDXSyNZVP5Qg76oKu